Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder

Next Previous
Trial Profile

A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion/trazodone (Primary) ; Bupropion
  • Indications Decreased libido
  • Focus Therapeutic Use
  • Acronyms PURPLE
  • Sponsors S1 Biopharma

    • Most Recent Events

    • 04 Jan 2019 According to a S1 Biopharma media release, expanded analysis of Phase 2a data will be presented at during the International Society for the Study of Women's Sexual Health (ISSWSH) and the International Society for Sexual Medicine (ISSM) Joint Meeting 2019.
    • 27 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Mar 2014 Results data for the phase IIa part of this trial are expected in the second quarter of 2014, according to a S1 Biopharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top